Sexual Side Effects
Sexual impairment is frequently associated with breast and pelvic cancers, but patients with digestive cancer also experience this effect. In this study, researchers assessed sexual activity, dysfunction, sexual quality of life, and need for oncosexology care among patients with gastrointestinal cancers.
Most centers reported having no sexual aids available for patients, according to researchers.
Rates of erectile dysfunction and urinary incontinence at 1, 2, and 3 years after radical surgery are not higher among men who have multiple prostate biopsies while on active surveillance for prostate cancer.
Investigators conducted a review of available biologic and psychosocial interventions that address sexual dysfunction in women arising from cancer diagnosis and treatment.
The impact of oral squamous cell carcinoma (OSCC) diagnosis and treatment on sexual behavior and relationship stress with respect to HPV status was evaluated in this study. Participants included patients with HPV-positive and HPV-negative disease, as well as partners.
Survivors of childhood cancer who received certain neurotoxic therapies are less likely to have had sexual intercourse or to be in an intimate relationship, researchers found.
Radiation therapy delivered to the critical vessels surrounding the prostate can result in erectile dysfunction and bladder and renal irritation. Vessel-sparing radiation and an improved understanding of the anatomy of the prostate can reduce these effects.
Researchers observed significant changes in health-related quality of life (HRQoL), depression, and sexual function among patients with breast cancer receiving chemotherapy.
Slightly higher odds of melanoma for men on erectile dysfunction (ED) drugs were recorded, but lifestyles are probable culprit.
Gardasil protects against genital warts and anal cancer in both girls and boys, and against vulvar cancer and vaginal cancer in girls.
High rates of preserved sexual function seen with combination beam plus brachytherapy for prostate cancer.
A new study has found that the levonorgestrel-releasing intrauterine system, or progesterone-releasing IUD, may be associated with a higher than expected incidence of breast cancer.
Adult and young adult cancer survivors face cognitive and sexual late effects from cancer and its treatment, according to data compiled from an online cancer survivorship care planning tool presented at the 2014 ASCO Annual Meeting.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- Seeking Reliable Information on Herbal Products
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|